Interventions of Interest

  • tafamidis (Vyndamax®/Vyndaqel®, Pfizer Inc.)
  • acoramidis (BridgeBio Pharma, Inc)
  • vutrisiran (Amvuttra®, Alnylam Pharmaceuticals, Inc.)

The independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for tafamidis, acoramidis, and vutrisiran when compared to no disease-specific therapy. Tafamidis and acoramidis would achieve common thresholds for cost-effectiveness if priced between $13,600 to $39,000 per year.

Final Documents

Final Evidence Report and Meeting SummaryDownload
Final Policy RecommendationsDownload
Report-at-a-GlanceDownload

For questions please contact info@icer.org.

View the Key Stakeholder List.

Draft Evidence ReportDownload
Response to Public CommentsDownload

ICER’s Chief Medical Officer David Rind, MD:

“The independent panel confirmed the substantial clinical benefits of treating ATTR-CM with either a stabilizer or an RNA silencer, but also that the current price for tafamidis is much too high.The panel disagreed with ICER’s conclusion that there is clear evidence for adding the RNA silencer vutrisiran to tafamidis in treating ATTR-CM, though the ICER research team stands by this conclusion. This adds even greater concerns around pricing, since combination therapy with drugs priced out of alignment with their clinical benefits will be extremely expensive and create strains in the health system.”